Dual approach of Tesamorelin… To our knowledge, this is the first study to employ a dual transcriptomic and proteomic approach to identify novel circulating protein signatures and therapeutic targets for NAFLD in PLWH. In addition, these results are demonstrated in a randomized trial with the presence of a placebo comparator group, and the availability of detailed phenotypic data on study participants.
https://www.nature.com/articles/s41598-021-89966-y